menu search

ADMA / ADMA Biologics: FY22 Numbers Key Inflection Point

ADMA Biologics: FY22 Numbers Key Inflection Point
ADMA Biologics continues to outperform benchmarks, after offering investors a source of tactical alpha across the past 18 months. The market continues to reward its hypothesis in treating primary humoral immunodeficiency. Read More
Posted: Jan 15 2023, 01:29
Author Name: Seeking Alpha
Views: 110821

ADMA News  

Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know

By Zacks Investment Research
November 2, 2023

Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know

Adma Biologics (ADMA) closed the most recent trading day at $3.45, moving -1.99% from the previous trading session. more_horizontal

Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note

By Zacks Investment Research
October 27, 2023

Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note

Adma Biologics (ADMA) closed at $3.31 in the latest trading session, marking a +0.91% move from the prior day. more_horizontal

Adma Biologics (ADMA) Rises As Market Takes a Dip: Key Facts

By Zacks Investment Research
October 17, 2023

Adma Biologics (ADMA) Rises As Market Takes a Dip: Key Facts

In the most recent trading session, Adma Biologics (ADMA) closed at $3.44, indicating a +1.78% shift from the previous trading day. more_horizontal

Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why

By Zacks Investment Research
October 9, 2023

Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why

In the closing of the recent trading day, Adma Biologics (ADMA) stood at $3.34, denoting a -0.3% change from the preceding trading day. more_horizontal

Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?

By Zacks Investment Research
September 13, 2023

Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about more_horizontal

Why Shares of ADMA Biologics Are Climbing Thursday

By The Motley Fool
August 10, 2023

Why Shares of ADMA Biologics Are Climbing Thursday

ADMA grew revenue and trimmed its losses compared to the same quarter a year ago. The company increased revenue guidance for 2023, 2024, and 2025. more_horizontal

ADMA Biologics (ADMA) to Report Q2 Earnings: What's in Store?

By Zacks Investment Research
July 28, 2023

ADMA Biologics (ADMA) to Report Q2 Earnings: What's in Store?

On ADMA Biologics' (ADMA) Q2 earnings call, investors will likely focus on the sales performance of its immune deficiency disorder drugs. more_horizontal


Search within

Pages Search Results: